A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Relapsed · Refractory · Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

China, Shanghai Mengchao Cancer Hospital, Shanghai, China
Contact: Study coordinator (j x Lou) · loujx@shcell.com · 0086-18911335396

Study leads

Jinxing Lou
Principal Investigator
China, Shanghai Mengchao Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Plasma Cell Leukemia

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia (PCL)

Abroad (travel likely)RecruitingPHASE2

Changchun, China

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)

IsraelRecruitingPHASE3

Birmingham, United States · Los Angeles, United States

Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

Relapsed Leukemia · Refractory Leukemia

Abroad (travel likely)RecruitingPHASE1

Beijing, China